Meta Biomed Statistics

Total Valuation

Meta Biomed has a market cap or net worth of KRW 121.92 billion. The enterprise value is 126.51 billion.

Market Cap	121.92B
Enterprise Value	126.51B

Important Dates

The next estimated earnings date is Wednesday, May 14, 2025.

Earnings Date	May 14, 2025
Ex-Dividend Date	Dec 27, 2024

Share Statistics

Meta Biomed has 22.83 million shares outstanding. The number of shares has increased by 18.55% in one year.

Current Share Class	22.83M
Shares Outstanding	22.83M
Shares Change (YoY)	+18.55%
Shares Change (QoQ)	-18.88%
Owned by Insiders (%)	25.44%
Owned by Institutions (%)	5.14%
Float	17.02M

Valuation Ratios

The trailing PE ratio is 8.19.

PE Ratio	8.19
Forward PE	n/a
PS Ratio	1.30
PB Ratio	1.27
P/TBV Ratio	1.33
P/FCF Ratio	10.40
P/OCF Ratio	5.39
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 5.70, with an EV/FCF ratio of 10.80.

EV / Earnings	5.65
EV / Sales	1.35
EV / EBITDA	5.70
EV / EBIT	7.35
EV / FCF	10.80

Financial Position

The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.58.

Current Ratio	1.28
Quick Ratio	0.94
Debt / Equity	0.58
Debt / EBITDA	2.53
Debt / FCF	4.79
Interest Coverage	4.60

Financial Efficiency

Return on equity (ROE) is 26.25% and return on invested capital (ROIC) is 7.99%.

Return on Equity (ROE)	26.25%
Return on Assets (ROA)	7.00%
Return on Invested Capital (ROIC)	7.99%
Return on Capital Employed (ROCE)	16.61%
Revenue Per Employee	347.00M
Profits Per Employee	82.67M
Employee Count	271
Asset Turnover	0.61
Inventory Turnover	2.73

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +33.33% in the last 52 weeks. The beta is 0.61, so Meta Biomed's price volatility has been lower than the market average.

Beta (5Y)	0.61
52-Week Price Change	+33.33%
50-Day Moving Average	4,587.80
200-Day Moving Average	4,159.60
Relative Strength Index (RSI)	63.17
Average Volume (20 Days)	1,919,650

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Meta Biomed had revenue of KRW 94.04 billion and earned 22.40 billion in profits. Earnings per share was 658.59.

Revenue	94.04B
Gross Profit	47.36B
Operating Income	17.22B
Pretax Income	23.30B
Net Income	22.40B
EBITDA	22.20B
EBIT	17.22B
Earnings Per Share (EPS)	658.59

Full Income Statement

Balance Sheet

The company has 54.30 billion in cash and 56.12 billion in debt, giving a net cash position of -1.82 billion or -79.91 per share.

Cash & Cash Equivalents	54.30B
Total Debt	56.12B
Net Cash	-1.82B
Net Cash Per Share	-79.91
Equity (Book Value)	96.11B
Book Value Per Share	4,088.23
Working Capital	20.36B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 22.63 billion and capital expenditures -10.91 billion, giving a free cash flow of 11.72 billion.

Operating Cash Flow	22.63B
Capital Expenditures	-10.91B
Free Cash Flow	11.72B
FCF Per Share	513.30

Full Cash Flow Statement

Margins

Gross margin is 50.36%, with operating and profit margins of 18.31% and 23.82%.

Gross Margin	50.36%
Operating Margin	18.31%
Pretax Margin	24.77%
Profit Margin	23.82%
EBITDA Margin	23.61%
EBIT Margin	18.31%
FCF Margin	12.46%

Dividends & Yields

This stock pays an annual dividend of 30.00, which amounts to a dividend yield of 0.57%.

Dividend Per Share	30.00
Dividend Yield	0.57%
Dividend Growth (YoY)	50.00%
Years of Dividend Growth	1
Payout Ratio	2.04%
Buyback Yield	-18.55%
Shareholder Yield	-17.98%
Earnings Yield	18.38%
FCF Yield	9.61%

Dividend Details

Stock Splits

The last stock split was on April 23, 2010. It was a forward split with a ratio of 2.

Last Split Date	Apr 23, 2010
Split Type	Forward
Split Ratio	2

Scores

Meta Biomed has an Altman Z-Score of 2.08. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.08
Piotroski F-Score	n/a